FASE II ONDERZOEK NAAR DEEFFECTIVITEIT VAN PAZOPANIB BIJ PATIËNTEN MET BAARMOEDERKANKER.
Recruiting
- Conditions
- Metastatic or locally advanced endometrial cancer not amenable to other therapy
- Registration Number
- NL-OMON26478
- Lead Sponsor
- niversity Medical Center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 55
Inclusion Criteria
1. Written informed consent;
2. Age ≥ 18 years;
Exclusion Criteria
1. Prior malignancy. Note: Subjects who have had another malignancy and have been disease-free for 5 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible;
2. History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal
carcinomatosis, except for individuals who have previously-treated CNS metastases, are
asymptomatic, with no radiological signs of progression and have had no requirement for
steroids or anti-seizure medication for 6 months prior to first dose of study drug;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients free of progression at 3 months.
- Secondary Outcome Measures
Name Time Method 1. Response rate;<br /><br>2. Progression free survival;<br /><br>3. Overall survival;<br /><br>4. Tolerability/toxicity.